We develop and manufacture lentiviral vectors as a European leader working under both EMA and FDA standards. The lentiviral vectors produced by VIVEbiotech are administered both ex-vivo and in-vivo to treat a range of disorders, including haematological and solid cancers, and rare diseases.

We are a Contract Development and Manufacturing Organization (CDMO) with over 40 biotech companies worldwide that have placed their trust in us.

Corporate video

A solid project with its own personality

Our roots are 100% Guipuzcoan. Since 2015 we have spearheaded the creation of an ecosystem in our region specialized in health-related biotechnology aimed at personalized precision medicine.

Our stable international clients and large-scale projects allow us to consolidate our structure and continue to grow sustainably, positioning our company and our region at the forefront of the medicine of the future on a global level.


Advanced Therapies Unit created.


Good manufacturing practices (GMP) approved by the Spanish Agency for Medicine and Health Products (AEMPS).


Lentivirus Vector Unit for use in research.


UNE - EN ISO 9001-2008


VIVEbiotech created.

2015 - Today

US, European, Asian and Australian customers

Compliance with EMA and FDA regulations

Expansion plan completed in 2021

One of the few companies fully focused on lentiviral vectors

Timely slot availability

Members of

Collaborate with

Project with a future

These are exciting times in the world of biotechnology and health, with realistic expectations for cures for many pathologies. VIVEbiotech is one of the players making this possible. In 2021 we opened a new facility with state-of-the-art equipment and capacity for clinical and commercial production phases as a stepping stone to VIVEbiotech's future strategic goals.